News & Updates

AURORA shines light on novel drug for lupus nephritis

18 Jun 2020 by

The novel calcineurin inhibitor (CNI) voclosporin showed superiority over placebo on a background of standard-of-care (SOC) in patients with active lupus nephritis (LN), the AURORA* trial has shown.

AURORA shines light on novel drug for lupus nephritis

18 Jun 2020

$Abaloparatide good for fracture risk reduction in younger postmenopausal women$

Abaloparatide good for fracture risk reduction in younger postmenopausal women

18 Jun 2020 by

The anabolic agent abaloparatide proves beneficial to younger postmenopausal women at high risk of fractures, producing substantial improvements in bone mass density, according to a subgroup analysis of the ACTIVE* trial.

Abaloparatide good for fracture risk reduction in younger postmenopausal women

18 Jun 2020

OPRX-106 for mild-to-moderate UC performs well in phase IIa trial

18 Jun 2020

Oral administration of the nonabsorbable OPRX-106 shows potential in the treatment of mild-to-moderate ulcerative colitis (UC), delivering favourable anti-inflammatory immune modulation without concurrent immune suppression, according to the results of a phase IIa trial.

OPRX-106 for mild-to-moderate UC performs well in phase IIa trial

18 Jun 2020

Remdesivir gets SG nod for severe COVID-19

17 Jun 2020 by

Singapore’s Health Sciences Authority (HSA) has granted a conditional approval to remdesivir for the treatment of severe COVID-19, sparking hope for that elusive cure.

Remdesivir gets SG nod for severe COVID-19

17 Jun 2020

Dupilumab shows promise in bullous pemphigoid

17 Jun 2020

Use of dupilumab appears to confer benefits in patients with bullous pemphigoid (BP), results of a recent study have shown. Treatment has resulted in disease clearance or satisfactory response in majority of the patients, including those in whom previous conventional therapy has failed.

Dupilumab shows promise in bullous pemphigoid

17 Jun 2020

eGFR dip does not influence outcomes in T2D patients on empagliflozin

17 Jun 2020 by

An eGFR* decline of >10 percent did not appear to influence kidney outcomes in individuals receiving empagliflozin for type 2 diabetes, according to data presented at ERA-EDTA 2020.

eGFR dip does not influence outcomes in T2D patients on empagliflozin

17 Jun 2020

Belimumab improves renal response in lupus nephritis

16 Jun 2020 by

Adding belimumab to standard maintenance therapy significantly improves renal response in patients with active lupus nephritis compared with standard therapy alone, according to the BLISS-LN study presented at the ERA-EDTA 2020 Meeting.

Belimumab improves renal response in lupus nephritis

16 Jun 2020

Dabigatran use cuts risk of S. aureus bacteraemia in AF patients

16 Jun 2020

Among patients with atrial fibrillation (AF), treatment with the direct thrombin inhibitor dabigatran results in a significantly lower incidence of Staphylococcus aureus bacteraemia as compared with factor Xa-inhibitors, a study has shown.